• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一名慢性淋巴细胞白血病患者在接受依鲁替尼治疗期间出现自发性前房积血。

Spontaneous Hyphema during Ibrutinib Treatment in a CLL Patient.

作者信息

Aldecoa Kim Abbegail Tan, Macaraeg Chef Stan L, Dadlani Akash, Yadlapalli Sri

机构信息

Department of Internal Medicine, Trinity Health Oakland, Pontiac, MI, USA.

Wayne State University, Detroit, MI, USA.

出版信息

Case Rep Hematol. 2023 Dec 14;2023:1691996. doi: 10.1155/2023/1691996. eCollection 2023.

DOI:10.1155/2023/1691996
PMID:38130705
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10735723/
Abstract

Ibrutinib is an oral, first-line, targeted therapy for chronic lymphocytic leukemia (CLL). Commonly reported adverse events are diarrhea, fatigue, and musculoskeletal pain, but rarely it has been associated with visual disturbances. Here, we present a rare case of spontaneous hyphema in a 60-year-old patient with a known diagnosis of CLL on ibrutinib treatment.

摘要

依鲁替尼是一种用于慢性淋巴细胞白血病(CLL)的口服一线靶向治疗药物。常见的不良事件包括腹泻、疲劳和肌肉骨骼疼痛,但它很少与视觉障碍相关。在此,我们报告一例60岁已知诊断为CLL且正在接受依鲁替尼治疗的患者发生自发性前房积血的罕见病例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b59a/10735723/eeacdf13d13c/CRIHEM2023-1691996.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b59a/10735723/eeacdf13d13c/CRIHEM2023-1691996.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b59a/10735723/eeacdf13d13c/CRIHEM2023-1691996.001.jpg

相似文献

1
Spontaneous Hyphema during Ibrutinib Treatment in a CLL Patient.一名慢性淋巴细胞白血病患者在接受依鲁替尼治疗期间出现自发性前房积血。
Case Rep Hematol. 2023 Dec 14;2023:1691996. doi: 10.1155/2023/1691996. eCollection 2023.
2
Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia: A systematic review and meta-analysis of randomized trials.与依鲁替尼治疗老年慢性淋巴细胞白血病相关的药物不良事件:随机试验的系统评价和荟萃分析
Medicine (Baltimore). 2019 Aug;98(33):e16915. doi: 10.1097/MD.0000000000016915.
3
Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.真实世界中伊布替尼在慢性淋巴细胞白血病中的剂量减少、暂停和停药。
Future Oncol. 2021 Dec;17(35):4959-4969. doi: 10.2217/fon-2021-0964. Epub 2021 Nov 16.
4
A Rare Side Effect of Ibrutinib: Tumor Lysis Syndrome.依鲁替尼的一种罕见副作用:肿瘤溶解综合征。
Medeni Med J. 2021;36(2):176-179. doi: 10.5222/MMJ.2021.56424. Epub 2021 Jun 18.
5
Pure red cell aplasia occurring during ibrutinib therapy for chronic lymphocytic leukemia.伊布替尼治疗慢性淋巴细胞白血病期间发生纯红细胞再生障碍。
J Oncol Pharm Pract. 2023 Dec;29(8):2031-2036. doi: 10.1177/10781552231189192. Epub 2023 Jul 30.
6
Health-related quality of life and treatment satisfaction in Chronic Lymphocytic Leukemia (CLL) patients on ibrutinib compared to other CLL treatments in a real-world US cross sectional study.在一项真实世界的美国横断面研究中,与其他 CLL 治疗相比,接受伊布替尼治疗的慢性淋巴细胞白血病(CLL)患者的健康相关生活质量和治疗满意度。
PLoS One. 2022 Oct 6;17(10):e0270291. doi: 10.1371/journal.pone.0270291. eCollection 2022.
7
Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study.伊布替尼治疗慢性淋巴细胞白血病患者的真实世界临床结局和不良事件:一项单中心回顾性研究。
Medicina (Kaunas). 2023 Feb 9;59(2):324. doi: 10.3390/medicina59020324.
8
Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.依鲁替尼治疗慢性淋巴细胞白血病:关注不良事件、耐药性及依鲁替尼之外的新方法
Ann Hematol. 2017 Jul;96(7):1175-1184. doi: 10.1007/s00277-017-2973-2. Epub 2017 Mar 24.
9
Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: A report from the Polish Adult Leukemia Study Group (PALG).在同情使用项目中治疗复发或难治性慢性淋巴细胞白血病的患者中停用伊布替尼:来自波兰成人白血病研究组(PALG)的报告。
Adv Clin Exp Med. 2019 Aug;28(8):1051-1057. doi: 10.17219/acem/99911.
10
A Novel Case of Penile Gangrene in a Patient Treated with Ibrutinib for Chronic Lymphocytic Leukemia.一例接受伊布替尼治疗慢性淋巴细胞白血病患者发生阴茎坏疽的罕见病例。
Case Rep Oncol Med. 2016;2016:6980198. doi: 10.1155/2016/6980198. Epub 2016 Nov 23.

本文引用的文献

1
Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner.依鲁替尼以一种不依赖布鲁顿酪氨酸激酶(BTK)的方式抑制血管生成和肿瘤发生。
Pharmaceutics. 2022 Sep 5;14(9):1876. doi: 10.3390/pharmaceutics14091876.
2
Cystoid macular edema secondary to ibrutinib.依鲁替尼继发的黄斑囊样水肿
Am J Ophthalmol Case Rep. 2022 Feb 18;26:101436. doi: 10.1016/j.ajoc.2022.101436. eCollection 2022 Jun.
3
Ibrutinib-related uveitis: A case series.依鲁替尼相关性葡萄膜炎:病例系列
Am J Ophthalmol Case Rep. 2022 Jan 22;25:101300. doi: 10.1016/j.ajoc.2022.101300. eCollection 2022 Mar.
4
Ibrutinib-related uveitis: A report of two severe cases.依鲁替尼相关葡萄膜炎:两例严重病例报告。
Eur J Ophthalmol. 2022 Jul;32(4):NP94-NP97. doi: 10.1177/11206721211001268. Epub 2021 Mar 15.
5
Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics.生物制剂、靶向药物和传统化疗药物已知的和新出现的眼部毒性。
Graefes Arch Clin Exp Ophthalmol. 2019 Aug;257(8):1771-1781. doi: 10.1007/s00417-019-04337-8. Epub 2019 May 16.
6
Anterior chamber fibrinoid syndrome after cataract extraction in a patient on ibrutinib for B-cell chronic lymphocytic leukemia: a case report and review of the literature.1例接受伊布替尼治疗B细胞慢性淋巴细胞白血病的患者白内障摘除术后前房纤维蛋白样综合征:病例报告及文献复习
J Med Case Rep. 2018 Nov 16;12(1):349. doi: 10.1186/s13256-018-1822-9.
7
Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated with ibrutinib.一名接受依鲁替尼治疗的慢性淋巴细胞白血病患者出现双侧黄斑囊样水肿。
Leuk Lymphoma. 2019 Mar;60(3):842-844. doi: 10.1080/10428194.2018.1508673. Epub 2018 Sep 6.
8
Ocular Toxicity of Tyrosine Kinase Inhibitors.酪氨酸激酶抑制剂的眼部毒性
Oncol Nurs Forum. 2016 Mar;43(2):235-43. doi: 10.1188/16.ONF.235-243.
9
Ocular Toxicity in Metastatic Melanoma Patients Treated With Mitogen-Activated Protein Kinase Kinase Inhibitors: A Case Series.丝裂原活化蛋白激酶激酶抑制剂治疗转移性黑色素瘤患者的眼部毒性:病例系列
Am J Ophthalmol. 2015 Nov;160(5):959-967.e1. doi: 10.1016/j.ajo.2015.07.035. Epub 2015 Jul 29.
10
MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity.MEK抑制剂:一类具有眼部毒性的新型化疗药物。
Eye (Lond). 2015 Aug;29(8):1003-12. doi: 10.1038/eye.2015.82. Epub 2015 Jun 5.